This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogène
This VLDLR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 484-510 amino acids from the Central region of human VLDLR.
VLDL
Reactivité: Humain, Rat
WB, FACS, IHC (p), IF
Hôte: Souris
Monoclonal
VLDLR-1337
unconjugated
Indications d'application
For FACS starting dilution is: 1:25
For IHC-P starting dilution is: 1:25
For WB starting dilution is: 1:2000
Restrictions
For Research Use only
Format
Liquid
Concentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. This gene encodes a lipoprotein receptor that is a member of the LDLR family and plays important roles in VLDL-triglyceride metabolism and the reelin signaling pathway. Mutations in this gene cause VLDLR-associated cerebellar hypoplasia. Alternative splicing generates multiple transcript variants encoding distinct isoforms for this gene. [provided by RefSeq].